PremiumThe FlyActinium enrolls first patient on the trial studying Iomab-ACT Promising Preclinical Data and Strong Financial Position Support Buy Rating for Actinium Pharmaceuticals Positive Buy Rating for Actinium Pharmaceuticals Driven by Promising Preclinical Data and Strategic Collaborations PremiumRatingsActinium Pharmaceuticals: Strategic Advancements and Financial Stability Signal Undervalued Opportunity Biotech Alert: Searches spiking for these stocks today Actinium announces positive ATNM-400 results in prostate cancer PremiumRatingsPromising Phase 1b Trial Results for Actinium Pharmaceuticals’ Actimab-A in r/r AML Support Buy Rating Actinium Pharmaceuticals: Strategic Clinical Advancements and Innovative Trials Drive Buy Rating Actinium Pharmaceuticals launches clinical trial for Actimab-A in combination 
